



**AstraZeneca** 


**1427 Rec'd PCT/PTO 02 FEB 2006**

PE

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: BALGANESH et al	Filing Date: Not yet assigned
Application No.: 10/550647 ✓	Attorney Docket No.: 101009-1P US
PCT Application No: PCT/GB2004/001272	Examiner: Not yet assigned
Title: Method	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 27, 2006.



Signature  
Bernadette Holder

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

**AstraZeneca** R&D Boston  
A business unit of AstraZeneca Pharmaceuticals LP  
35 Gatehouse Drive  
Waltham MA 02451  
USA

**Tel** +1 781-839-4000  
**Fax** +1 781-839-4500


### REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of the **first Office Action** on the merits.

It is respectfully requested that each of the patents and publications listed on the attached Forms SB08 A and B, and other information contained herein, be considered by the Examiner and made of record in this application.


Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101009-1P US.

Respectfully submitted,

  
Name: Christine McCormack  
Dated: January 27, 2006  
Reg. No.: L0065  
Phone No.: 781-839-4693

Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham, MA 02451

Enclosures: Form SB08A (1 pages - 2 documents)  
Form SB08B (1 pages - 4 documents)  
Search Report  
IPER  
Return Receipt Postcard



Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/550647
--------------------	-----------

Filing Date	Not yet assigned
-------------	------------------

First Named Inventor	BALGANESH, Tanjore, SoundaRajan
----------------------	---------------------------------

Art Unit	Not yet assigned
----------	------------------

Examiner Name	Not yet assigned
---------------	------------------

Attorney Docket No. 101009-1P US

**SHEET 1 of 2**

## U.S. PATENT DOCUMENTS

Examiner  
Initials\*Cite  
No. 1

Document Number

Number - Kind Code<sup>2</sup> (if known)Publication Date  
MM-DD-YYYYName of Patentee or  
Applicant of Cited Document

Pages, Columns, Lines, Where  
Relevant Passages or Relevant  
Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner  
Initials\*Cite  
No<sup>1</sup>

Foreign Patent Document

Country Code<sup>3</sup> - Number<sup>4</sup> - Kind Code<sup>5</sup> (if known)

Publication Date  
MM-DD-YYYY

Name of Patentee or  
Applicant of Cited  
Document

Page	Column	Line	Where Relevant Passages or Relevant Figures Appear
1	1	1	1
1	1	2	2
1	1	3	3
1	1	4	4
1	1	5	5
1	1	6	6
1	1	7	7
1	1	8	8
1	1	9	9
1	1	10	10
1	1	11	11
1	1	12	12
1	1	13	13
1	1	14	14
1	1	15	15
1	1	16	16
1	1	17	17
1	1	18	18
1	1	19	19
1	1	20	20
1	1	21	21
1	1	22	22
1	1	23	23
1	1	24	24
1	1	25	25
1	1	26	26
1	1	27	27
1	1	28	28
1	1	29	29
1	1	30	30
1	1	31	31
1	1	32	32
1	1	33	33
1	1	34	34
1	1	35	35
1	1	36	36
1	1	37	37
1	1	38	38
1	1	39	39
1	1	40	40
1	1	41	41
1	1	42	42
1	1	43	43
1	1	44	44
1	1	45	45
1	1	46	46
1	1	47	47
1	1	48	48
1	1	49	49
1	1	50	50
1	1	51	51
1	1	52	52
1	1	53	53
1	1	54	54
1	1	55	55
1	1	56	56
1	1	57	57
1	1	58	58
1	1	59	59
1	1	60	60
1	1	61	61
1	1	62	62
1	1	63	63
1	1	64	64
1	1	65	65
1	1	66	66
1	1	67	67
1	1	68	68
1	1	69	69
1	1	70	70
1	1	71	71
1	1	72	72
1	1	73	73
1	1	74	74
1	1	75	75
1	1	76	76
1	1	77	77
1	1	78	78
1	1	79	79
1	1	80	80
1	1	81	81
1	1	82	82
1	1	83	83
1	1	84	84
1	1	85	85
1	1	86	86
1	1	87	87
1	1	88	88
1	1	89	89
1	1	90	90
1	1	91	91
1	1	92	92
1	1	93	93
1	1	94	94
1	1	95	95
1	1	96	96
1	1	97	97
1	1	98	98
1	1	99	99
1	1	100	100

7

WO 03/074728 A2

12-09-2003

The University of  
British Columbia

WO 03/084947 A1

16-10-2003

**Axxima  
Pharaceuticals  
AG**


**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/550647
Filing Date	Not yet assigned
First Named Inventor	BALGANESH, Tanjore, SoundaRajan
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	101009-1P US

SHEET 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	Koul <i>et al</i> "Serine/Threonine Protein Kinases PknF and PknG of Mycobacterium Tuberculosis: Characterization and Localization" Microbiology, 2001, Vol. 147, pp. 2307-2314	<input type="checkbox"/>
	AB	Yossef <i>et al</i> "The Eukaryotic-like Ser/thr Protein Kinases of Mycobacterium Tuberculosis" Trends in Microbiology, Elsevier Science Ltd., 2000, Vol. 8 pp. 238-244	<input type="checkbox"/>
	AC	McKinney <i>et al</i> "Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase" Nature (London), 2000, Vol. 406, pp. 735-738	<input type="checkbox"/>
	AD	Bentrup <i>et al</i> "Characterization of Activity and Expression of Isocitrate Lyase in Micobacterium Avium and Mycobacterium Tuberculosis" Journal of Bacteriology, 1999, Vol. 181, pp. 7161-7167	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.